GGrantIndex
← Leaderboards

James Francis McGinnis

University Of Oklahoma Hlth Sciences Ctr

$8,319,898
Attributed
$8,319,898
Total exposure
13
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $767.7K · FY200520
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$8,319,898 · 13

By mechanism

R01$3,975,585 · 3
P30$2,589,949 · 2
P20$1,199,087 · 7
R21$555,277 · 1

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “Vision

Research focus

VisionFluorescence MicroscopyLightStainsImageHistologyOpticsEquipmentProductivityVision ResearchFundingServicesResearch PersonnelApoptosisStaining MethodAge Related Macular DegenerationIn VivoParticleReactive Oxygen SpeciesRetinaGenesPreventAcutePhotoreceptors

Grant awards (35)

Cellular Imaging and Morphometric Analysis Core$214,738
P30 · FY2020 · EY · contact PI
Cellular Imaging and Morphometric Analysis Core$214,738
P30 · FY2019 · EY · contact PI
Cellular Imaging and Morphometric Analysis Core$214,738
P30 · FY2018 · EY · contact PI
Cellular Imaging and Morphometric Analysis Core$214,738
P30 · FY2017 · EY · contact PI
Cellular Imaging and Morphometric Analysis Core$214,738
P30 · FY2016 · EY · contact PI
Prolonged Inhibition of Pathologic Neovascularization by Catalytic Antioxidants$537,539
R01 · FY2015 · EY · contact PI
Prolonged Inhibition of Pathologic Neovascularization by Catalytic Antioxidants$536,919
R01 · FY2014 · EY · contact PI
Prolonged Inhibition of Pathologic Neovascularization by Catalytic Antioxidants$522,411
R01 · FY2013 · EY · contact PI
Prolonged Inhibition of Pathologic Neovascularization by Catalytic Antioxidants$583,612
R01 · FY2012 · EY · contact PI
COBRE:OUHSC: IMAGE ACQUISITION & PRODUCTION CORE$226,613
P20 · FY2011 · RR · contact PI
Prevention of Inherited Retinal Diseases by Therapeutic Rare Earth Nanoparticles$363,220
R01 · FY2010 · EY · contact PI
COBRE:OUHSC: IMAGE ACQUISITION & PRODUCTION CORE$218,937
P20 · FY2010 · RR · contact PI
Prevention of Inherited Retinal Diseases by Therapeutic Rare Earth Nanoparticles$374,845
R01 · FY2009 · EY · contact PI
COBRE:OUHSC: IMAGE ACQUISITION & PRODUCTION CORE$210,414
P20 · FY2009 · RR · contact PI
Pharmacokinetics of Therapeutic Nanoparticles in the CNS$182,445
R21 · FY2009 · EY · contact PI
CORE--IMAGE ACQUISTION & ANALYSIS$258,002
P30 · FY2008 · EY · contact PI
COBRE:OUHSC: IMAGE ACQUISITION & PRODUCTION CORE$195,145
P20 · FY2008 · RR · contact PI
Pharmacokinetics of Therapeutic Nanoparticles in the CNS$180,413
R21 · FY2008 · EY · contact PI
CORE--IMAGE ACQUISTION & ANALYSIS$255,616
P30 · FY2007 · EY · contact PI
Pharmacokinetics of Therapeutic Nanoparticles in the CNS$192,419
R21 · FY2007 · EY · contact PI
COBRE:OUHSC: IMAGE ACQUISITION & PRODUCTION CORE$103,151
P20 · FY2007 · RR · contact PI
CORE--IMAGE ACQUISTION & ANALYSIS$225,610
P30 · FY2006 · EY · contact PI
COBRE:OUHSC: IMAGE ACQUISITION & PRODUCTION CORE$98,125
P20 · FY2006 · RR · contact PI
CORE--IMAGE ACQUISTION &ANALYSIS$221,215
P30 · FY2005 · EY
COBRE:OUHSC: IMAGE ACQUISITION &PRODUCTION CORE$67,866
P20 · FY2005 · RR
CORE--IMAGE ACQUISTION &ANALYSIS$219,287
P30 · FY2004 · EY
COBRE:OUHSC: IMAGE ACQUISITION &PRODUCTION CORE$78,836
P20 · FY2004 · RR
ANTIBODY-MEDIATED DEATH OF MAMMALIAN PHOTORECEPTOR CELLS$296,549
R01 · FY2003 · EY
ANTIBODY-MEDIATED DEATH OF MAMMALIAN PHOTORECEPTOR CELLS$296,549
R01 · FY2002 · EY
CORE--IMAGE ACQUISITION AND PRODUCTION$117,022
P30 · FY2002 · EY
ANTIBODY-MEDIATED DEATH OF MAMMALIAN PHOTORECEPTOR CELLS$5,615
R01 · FY2002 · EY
ANTIBODY-MEDIATED DEATH OF MAMMALIAN PHOTORECEPTOR CELLS$229,163
R01 · FY2001 · EY
CORE--IMAGE ACQUISITION AND PRODUCTION$117,022
P30 · FY2001 · EY
ANTIBODY-MEDIATED DEATH OF MAMMALIAN PHOTORECEPTOR CELLS$229,163
R01 · FY2000 · EY
CORE--IMAGE ACQUISITION AND PRODUCTION$102,485
P30 · FY2000 · EY